VRTX · News · 20260810N
Revenue Performance and Mix
VERTEX PHARMACEUTICALS INC / MA · 2026-08-10 · Importance 83 · Surprise 60 · In source text
Vertex reported Q2 2026 revenue of approximately $3.3 billion, exceeding analyst estimates. Revenue growth was driven by the cystic fibrosis portfolio and newer products including CASGEVY and JOURNAVX. The company raised its 2026 revenue guidance to $13.10–$13.20 billion.
Key facts
- Vertex Pharmaceuticals reported Q2 2026 revenue of $3.3 billion, surpassing estimates. source
- Vertex Pharmaceuticals said growth in Q2 2026 was driven by new products CASGEVY and JOURNAVX. source
- Vertex Pharmaceuticals reported strong Q2 2026 results, exceeding revenue estimates. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Vertex Pharmaceuticals reported Q2 2026 revenue of $3.3 billion, surpassing estimates. |